⌘K
t
| Date | 2 Oct 2023 |
| Time | 15:15:01 |
| Category | Miscellaneous |
| ID | 4134O |
Posting of Notice of GM and Annual Report
2 October 2023
EDX Medical Group plc ("EDX Medical" or the "Company"), which develops innovative digital diagnostic products and services supporting personalised treatment solutions for cancer, heart disease, neurology and infectious diseases, announces that a general meeting ("GM") will be held at 10 Stratton Street, London W1J 8LG on 25 October 2023 at 2:00 p.m.
The annual report and financial statements for the year ended 31 March 2023, Notice of GM and Form of Proxy will be posted today, 2 October 2023, to eligible shareholders. Electronic copies will be shortly available on the Company's website at: https://edxmedical.co.uk/documents/.
Contacts:
|
EDX Medical plc |
|
|
Dr Mike Hudson (Chief Executive Officer) |
+44 (0)7812 345 301 mike@edxmedical.co.uk |
|
|
|
|
Oberon Capital |
|
|
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking) |
+44 (0)20 3179 5300 |
|
|
|
|
Media House International |
|
|
Ramsay Smith (Executive Director)
Gary McQueen (Associate Director) |
+44 (0)7788 414856 ramsay@mediahouse.co.uk + 44 (0)7834 694609 gary@mediahouse.co.uk |
Notes for Editors:
About EDX Medical Group plc (www.edxmedical.co.uk)
EDX Medical Group plc develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, and infectious diseases. The company is listed on the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.
EDX Medical operates a molecular biology and diagnostics laboratory in Cambridge, UK, and 100%-owned subsidiary companies, Hutano Diagnostics Limited in Oxford, UK, and Torax Biosciences Ltd (www.toraxbiosciences.co.uk) in Ireland.
EDX Medical provides testing and genomic sequencing services, undertakes quality assurance, conducts research & development (R&D) and has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485. Key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).